About

Welcome to the IHS Healthcare and Pharma blog

Here you’ll find regular insights from our team of experts covering the global healthcare and pharmaceutical industries. Join us as we look at issues in Healthcare Policy, Market Access, Pricing and Reimbursement and R&D. Comments are welcome!

The IHS Healthcare Practice

The IHS Healthcare practice provides a portfolio of intelligence solutions for companies and organizations with interests in the pharmaceutical, biotech, generics and medical device sectors.

Learn more about our Healthcare & Pharmaceutical Industry Analysis solutions.

The team provides actionable insights to support strategic decision making, particularly in the fields of:

Who writes this blog?

This blog is written and maintained by analysts from the IHS Healthcare team, each with expertise in particular areas of the global healthcare and pharmaceutical industry.

Gustav Ando, Director of IHS Healthcare Practice, Healthcare, IHS
Gustav Ando leads the Healthcare Practice at IHS. Formerly a healthcare analyst, he has extensive experience in the fields of market access, therapeutic development, drug safety, emerging markets, and health outcomes.
Milena Izmirlieva, Senior Manager, Healthcare, IHS
Milena Izmirlieva is a senior manager in the Healthcare practice at IHS. Her areas of expertise include market access, pricing and reimbursement, generics and biosimilars, corporate strategies, and pharma promotion and advertising.
Jing Zhang, Healthcare Economist, IHS
Jing Zhang is a healthcare economist at IHS, responsible for healthcare and pharma forecast and analysis. Jing holds a Ph. D degree in economics from Temple University. Before joining IHS, Jing worked as an economist in the federal government at FDIC, National Credit Union Administration and IRS.
Praful Mehta, Senior Analyst, Healthcare, IHS
Praful Mehta is a practice leader within the IHS therapeutic area services. Praful has been a long-time advisor to senior teams within the pharma industry on issues of market competitiveness, business integration, and commercialization strategies.
Floriane Reinaud, Principal Analyst, Healthcare, IHS
Floriane Reinaud is a principal analyst at IHS Healthcare Practice. She is responsible for a global pharmaceutical pricing database and has developed in-depth knowledge and experience of P&R policies, market access strategies, and specialist topics, including orphan drugs and biosimilars.
Gaëlle Marinoni, Manager, Healthcare, IHS
Gaëlle Marinoni is a Manager at the IHS Healthcare Practice and heads the healthcare multi-client study practice. Previously a market access consultant, a Western European healthcare analyst, and a research scientist, she specialises in market access, pricing and reimbursement, and corporate strategies.
Sophia Walker, Senior Analyst, Healthcare, IHS
Sophia Walker is a senior analyst in the advanced markets team, with a focus on the oncology service. She has an extensive background in oncology clinical trials, as well as an expertise in market access and pricing and reimbursement.
Brendan Melck, Analyst, Healthcare, IHS
Brendan Melck is an analyst in the IHS Healthcare practice. He covers the Central and Eastern Europe region (as well as Italy and Greece). With a background as a general business analyst covering this region, he has built a solid understanding of the pharmaceutical regulatory environment and the issues affecting the industry in these countries.
Cameron Lockwood, Analyst, Healthcare, IHS
Cameron Lockwood is an analyst within the healthcare multi-client study team. He has a background in the life sciences, experience in market access, and specialises in the healthcare policy environment.
Anne-Charlotte Honoré, Analyst, Healthcare, IHS
Anne-Charlotte Honoré Senior Analyst, IHS
Anne-Charlotte Honoré is a Senior Analyst responsible for the IHS World Markets Pricing and Reimbursement service. She has in-depth expertise in pricing and reimbursement, healthcare policy and market access strategies across major markets.

Comments are closed.

Extract download: European Pharmacovigilence Reform multi client study
Dynamic Pharma Pricing 2012 Multi Client Study extract download

About This Blog

In this blog, our experts share regular insights on the global healthcare and pharma industry. Join us as we look at issues in Healthcare Policy, Market Access, Pricing and Reimbursement and R&D. Comments are welcome!
Download an extract — The New REAlity of Relative Effectiveness Assessment: International Comparison of Evolving Requirements

Enter your email address to follow this blog and receive notifications of new posts by email.

Download an Extract of Payer-Industry Partnerships in the Emerging Markets: Best Practices for Successful Market Access of New Pharmaceuticals
Read the complimentary special report on UK Drug Reimbursement: What would change with Value-Based Pricing?

IHS Healthcare Twitter feed

Follow

Get every new post delivered to your Inbox.

Join 159 other followers